A Phase II Study of Venetoclax and Ibrutinib in Patients With Chronic Lymphocytic Leukemia (CLL)

Trial Profile

A Phase II Study of Venetoclax and Ibrutinib in Patients With Chronic Lymphocytic Leukemia (CLL)

Recruiting
Phase of Trial: Phase II

Latest Information Update: 23 Apr 2018

At a glance

  • Drugs Ibrutinib (Primary) ; Venetoclax (Primary)
  • Indications Chronic lymphocytic leukaemia
  • Focus Therapeutic Use
  • Most Recent Events

    • 19 Mar 2018 Planned End Date changed from 1 Jul 2024 to 1 Jul 2025.
    • 12 Dec 2017 Preliminary results presented at the 59th Annual Meeting and Exposition of the American Society of Hematology
    • 13 Jul 2017 Planned number of patients changed from 78 to 160.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top